Phase 2 Trial Compares Cabazitaxel and ARPIs in Poor-Prognosis mCRPC After Docetaxel
/in Clinical Trial, Metastatic, Phase 2/by MaxLUNAR Trial Shows Combination Therapy Doubles Progression-Free Survival in Recurrent Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxASPIRE Trial Explores Early Chemotherapy Addition for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: 161Tb-PSMA Offers Hope After Lutetium Failure in mCRPC
/in Clinical Trial, Metastatic/by MaxEfficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxAZD6621: A T-Cell Therapy Targets Hidden Prostate Cancer Driver
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2: Tulmimetostat + ARPI Combo for mHSPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
- CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC December 11, 2025